Bimuno Prebiotic Powder (ORIGINAL)
Gut Health & Immunity
The health of the gut is fundamental both to general nutrition and to the avoidance of gastrointestinal disease. The beneficial gut bacteria, mainly Bifidobacteria, and the immune system are responsible for the prevention of penetration of immunogenic components and protection against pathogenic bacteria.
A positive bacterial balance is required to help maintain immune health and general wellbeing.
Probiotic supplements and foods may have a restricted role in the management of gut health due to the problems associated with survivability of the live bacteria and delivery to the large intestine1. 1st generation prebiotics (food source for the gut’s beneficial bacteria) lack the added specificity and functionality required to further enhance gut and immune health.
More about Bimuno® Prebiotic Powder
Bimuno® Prebiotic Powder was the first Bimuno® product to become available in the UK and is formulated to provide added functionality over probiotic supplements and 1st generation prebiotics.
Promoted as ‘Prebiotic Power for Your Gut’ this original Bimuno product is designed to provide a:
• Powerful prebiotic effect (increasing and strengthening beneficial bacteria)
• Powerful bifidogenic effect (increasing and strengthening immunity boosting Bifidobacteria)
• Unique anti-pathogenic action (preventing the attachment and colonization of G.I. pathogens).
It provides clinically proven gut and immune health benefits.
The Clinical Evidence
The Clinical evidence is as follows:
Prevention of Pathogenic G.I. bacteria colonisation2,3
Energising (increases and strengthens) the body’s immunity boosting bacteria (bifidobacteria)4
Enhancement of Immune Function in the Elderly5
Prevention of IBS symptoms6
Prevention of Travellers’ Diarrhoea7
Who can benefit from Bimuno® Prebiotic Powder?
Patients suffering from G.I. related problems and those who are proactive about their gut health and general wellbeing can benefit from taking Bimuno® Prebiotic Powder.
This particular Bimuno® product is more suitable for those who prefer powder as opposed to pastilles. It is also suitable for children aged 3 years to 11 years.
Broadly, the following individuals can benefit from Bimuno® Prebiotic Powder:
• Those feeling ‘run down’
• With digestive problems
• Recovering from illness
• On antibiotics
• About to enter hospital and are concerned about HAI’s
• Are about to travel abroad
• Are aged 55+ or are elderly
• Those who are proactive about their gut and immune health.
Recommending Bimuno® Prebiotic Powder
Bimuno® Prebiotic Powder is classed as a food supplement and does not have any of the warnings and contra-indications associated with medicinal products.
Although no adverse effects have been reported, it should be noted that Bimuno® Prebiotic Powder contains small amounts of lactose (from milk).
The product contains 30 sachets each containing 5.5g of powder. The active ingredient is galacto-oligosaccharides equivalent to a daily serving (dose) of 2.76g. It is free from artificial colours, flavours and preservatives and is gluten free. The lactose content is 1.1g* per daily serving. Per daily dose it contains 15 kcal, 1.9g of sugar and 0.03g of fat.
It is suitable for children aged 3 years and over and for adults.
Bimuno® Prebiotic Powder can be added to everyday food and drink e.g. cereal, yoghurt, coffee or tea.
The recommended serving is: Children 12 years and over and adults, 1 sachet (5.5g) daily. For children 3 to 11 years of age ½ a sachet daily (2.75g). Since the benefits build over time, a daily intake is recommended.
Reference:
1. Gibson GR et al. www.food.gov.uk/news/newsarchive/2005/mar/probiotics
2. Tzortzis et al. J Nutr 2005;135:1726-1731.
3. Searle LEJ et al. Journal of Medical Microbiology 2009;58:37-48.
4. Depeint F et al. Am J Clin Nutr 2008;87:785-91.
5. Vulevic J et al. Am J Clin Nutr 2008;88:1438-46.
6. Silk DBA et al. Aliment Pharmacol Ther 2009;29:508-518.
7. Drakoularakou A et al. European Journal of Clinical Nutrition 2010;64:146-152.
* Lactose doses of less than 10g per day are likely to be tolerated by most of the population of lactose deficient adults. EFSA Journal (2007) 565,1-6.